fgfr detection (Novus Biologicals)
Structured Review

Fgfr Detection, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgfr+detection/FGFR1+Antibody+(Lilly+patent+anti-FGFR-1)/pmc12541837-72-4-9
Average 93 stars, based on 6 article reviews
Images
1) Product Images from "TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation"
Article Title: TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation
Journal: Translational Lung Cancer Research
doi: 10.21037/tlcr-2025-690
Figure Legend Snippet: Kaplan-Meier curve showing OS probability among p40/TTF-1 double expressor NSCLC cases, comparing patients with FGFR1 overexpression and/or amplification (FGFR1alt) to those without these alterations (FGFR1wt). The P value was calculated using the log-rank test. FGFR, fibroblast growth factor receptor; NSCLC, non-small cell lung cancer; OS, overall survival; wt, wild-type.
Techniques Used: Over Expression, Amplification
Related Articles
Over Expression:Article Title: TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation Article Snippet: Additional IHC staining was conducted for p53 (clone DO-7, Dako/Agilent), p63 (clone DAK-p63, Dako/Agilent), PD-L1 (clone 22C3, Dako/Agilent), and FGFR1–4 using 4 μm formalin-fixed, paraffin-embedded (FFPE) tumor sections following standardized protocols.Additional IHC staining was conducted for p53 (clone DO-7, Dako/Agilent), p63 (clone DAK-p63, Dako/Agilent), PD-L1 (clone 22C3, Dako/Agilent), and FGFR1–4 using 4 μm formalin-fixed, paraffin-embedded (FFPE) tumor sections following standardized protocols.. Primary antibodies used for Amplification:Article Title: TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation Article Snippet: Additional IHC staining was conducted for p53 (clone DO-7, Dako/Agilent), p63 (clone DAK-p63, Dako/Agilent), PD-L1 (clone 22C3, Dako/Agilent), and FGFR1–4 using 4 μm formalin-fixed, paraffin-embedded (FFPE) tumor sections following standardized protocols.Additional IHC staining was conducted for p53 (clone DO-7, Dako/Agilent), p63 (clone DAK-p63, Dako/Agilent), PD-L1 (clone 22C3, Dako/Agilent), and FGFR1–4 using 4 μm formalin-fixed, paraffin-embedded (FFPE) tumor sections following standardized protocols.. Primary antibodies used for |